Immunoadsorption in steroid-refractory multiple sclerosis

Area of Science:

• Neuroimmunology
• Autoimmune diseases
• Clinical neurology

Background:

• Multiple sclerosis (MS) is an autoimmune disorder affecting both humoral and cellular immunity.
• Plasma exchange (PE) is guideline-recommended for steroid-refractory MS relapses, with 40-70% efficacy.
• Limited data exist on immunoadsorption (IA) for MS treatment.

Purpose of the Study:

• To evaluate the efficacy of immunoadsorption (IA) in treating multiple sclerosis (MS) relapses.
• To compare the efficacy of IA with plasma exchange (PE) in steroid-refractory MS relapses.

Main Methods:

• Review of 6 published studies on immunoadsorption (IA) treatment in various forms of MS.
• Analysis of 4 studies specifically focusing on steroid-refractory MS relapses.

Main Results:

• Significant clinical improvement observed in 73-85% of patients with steroid-refractory MS relapses treated with IA.
• No clinical improvement reported in MS patients with non-active relapsing-remitting or secondary progressive MS courses.
• IA demonstrates comparable efficacy to PE for steroid-refractory MS relapses, despite limited study data.

Conclusions:

• Immunoadsorption (IA) appears to be a viable treatment option for steroid-refractory multiple sclerosis (MS) relapses.
• IA shows comparable efficacy to plasma exchange (PE) in this patient group.
• Prospective trials are necessary to validate and expand upon these findings for MS management.